CA2316277C - Tablet for instant and prolonged release of one or more active substances - Google Patents
Tablet for instant and prolonged release of one or more active substances Download PDFInfo
- Publication number
- CA2316277C CA2316277C CA002316277A CA2316277A CA2316277C CA 2316277 C CA2316277 C CA 2316277C CA 002316277 A CA002316277 A CA 002316277A CA 2316277 A CA2316277 A CA 2316277A CA 2316277 C CA2316277 C CA 2316277C
- Authority
- CA
- Canada
- Prior art keywords
- layer
- active substance
- copolymers
- tablet according
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Abstract
The invention relates to a multilayer tablet for the instant and then prolonged release of active substances comprising at least two superposed layers, characterized in that: a first outer layer is composed of a mixture of excipients and of a first active substance, the said first layer allowing immediate release of the said first active substance; a second layer, arranged in contact with the said first layer, consists of a nonbiodegradable, inert porous polymeric matrix in which a second active substance is dispersed.
Description
TABLET FOR INSTANT AND PROLONGED RELEASE OF ONE OR MORE ACTIVE SUBSTANCES
The invention relates to solid galenic forms of the controlled release tablet type for the instant and then prolonged release of one or more active substances.
The importance of such galenic forms is undeniable. The immediate release of an active substance will ensure its practically instant bioavailability, which is particularly desirable in the case of patients suffering from acute conditions.
However, in the case of active substances having a short half-life, the therapeutic activity is only temporary. Now, a continuous and regular supply of active ingredient is often necessary for an effective therapy. To this end, numerous immediate- and prolonged-release systems have been developed.
Reference may be made, for example, to the following patents and applications of the state of the art: WO 96/03111, US 4,990,335, EP 352 190, BE 905 282, EP 106 443, EP 36 350, EP 615 444 and EP 220 670.
However, in the prior art systems, the kinetics of release of the active ingredient depend on many factors, such as the enzymatic activity and the pH
conditions which vary substantially from one individual to another and for the same individual, depending on whether they are on an empty stomach or not.
Furthermore, the pH conditions vary all along the gastrointestinal tract. Thus, it is difficult to predict in vivo, with precision, the profile for the release of a given substance after administration of the prior art instant- and prolonged-release systems.
The present invention aims to solve this problem by providing tablets which preserve their characteristics for the release of active substances regardless of the conditions of administration in vivo SUBSTtTUTE SHEET (RULE 26) _ 2 _ The tablets of the invention provide an excellent reproducibility of the results, while allowing an increased control of the rates of release during the phase of prolonged release of the active ingredient. By using the tablets of the invention, it becomes possible to optimize the supply of the active ingredients in the body while taking into account both the subject's tolerance to the active ingredient and the pharmacokinetic and metabolic profiles of the active ingredient.
Tablets of the invention are, moreover, advantageous from the point of view of the formulation of the active ingredients since a judicious choice of the excipients leads to tablets with high concentrations of active ingredients.
Thus, it is possible to produce tablets with very high doses, having an acceptable size for oral administration.
More precisely, the invention relates to multilayer tablets for the instant and then prolonged release of active substances comprising at least two superposed layers, characterized in that:
- a first outer layer is composed of a mixture .of excipients and of a first active substance, the said first layer allowing immediate release of the said first active substance;
- a second layer, arranged in contact with the said first layer, consists of a nonbiodegradable, inert porous polymeric matrix in which a second active substance is dispersed.
The second layer, which is arranged in contact with the first layer, is either completely enveloped by the first layer, or only partially covered by it.
In the first case, the two layers are concentric.
In the second case, only one of the surfaces of the second layer is in contact with the first layer: in the text which follows, this type of tablet is designated as "containing parallel layers" and the SUBSTITUTE SHEET (RULE 26) shape of the tablet is unimportant and is in particular ovoidal. It should be understood that in this case, the two layers have one outer surface, their other surface being in contact with one another.
The tablets of the invention are preferably bilayered. However, the invention also encompasses multilayer tablets, as long as they comprise the combination of the first and second layers defined above.
For some active ingredients, problems of stability of the active ingredient included in the prolonged-release matrix may exist. In this case, it is advantageous to opt for the preparation of tablets containing concentric layers.
The kinetics of release of the active ingredient depend, in each case, on the exact composition of the layer considered. It is by adapting the nature and the quantity of the excipients constituting the two layers that the kinetics of release can be modulated.
One characteristic of the first layer is that it disintegrates rapidly at the site of administration.
In contrast, the second layer is not biodegradable. Its matrix is inert in the sense that it does not react with the surrounding medium. The matrix of the second layer retains its physical and chemical integrity throughout the prolonged release of the active ingredient, regardless of the pH variations.
Since the first layer disintegrates instantly upon contact with an aqueous medium such as a physiological medium, it is easy to understand why the release of the first active substance is immediate.
In the case of the second layer and since the matrix constituting it is inert (it does not become eroded and does not swell in an aqueous medium), the release of the second active substance occurs by lixiviation and diffusion. The surrounding aqueous medium gradually penetrates into the inert porous matrix and then progressively, this aqueous medium SUBSTITUTE SHEET (RULE 26) dissolves the active substance dispersed in the inert matrix. The mechanism of diffusion being slow in essence, it can be understood why the release of the active ingredient is prolonged in this case.
Whereas the mechanism of disintegration of the first layer does not, or not to any great extent, depend on the nature of the active substance, it is clear that the more or less hydrophilic character of the active substance of the second layer can influence the kinetics of lixiviation/diffusion.
However, the invention is not limited as to the nature of the active substances. Each layer may contain a different active ingredient.
However, according to a specific embodiment of the invention, the first and second layers comprise the same active substance.
The active substances may be chosen in particular from any of the following groups (to designate the active substances, the international nonproprietary names have been adopted):
- medicaments which are active in asthma such as 2-ethoxymethyl-4(3H)-pteridinone and bronchodilators such as theophylline, and/or some anti-inflammatory agents or antihistaminics of the ketotifen type;
- medicaments which are active in the treatment of diabetes and its related complications of the neurological, nephrological, ocular or vascular type.
By way of example, there may be mentioned metformin, hypolipidaemic agents such as fenofibrate or pravastatin and anti-atheromatous agents in general;
- medicaments which are active in the treatment of alcoholism, such as acamprosate;
- peripheral analgesics, for example para-aminophenol derivatives such as paracetamol, salicylated derivatives such as aspirin, diflunisal, propionic acid derivatives such as ibuprofen, fenoprofen, ketoprofen, aminoquinoline derivatives such as floctafenine, pyrazolone derivatives such as noramidopyrine;
SUBS'TITUTE SHEET (RULE 26) - central analgesics such as dextropoxyphene, codeine, morphine, pethidine, dextromoramide, buprenorphine, nalbuphine, pentazocine;
- antispasmodics such as tiemonium, difemerine, phloroglucinol, trimebutine, pinaveriunn, prifinium;
- nonsteroidal anti-inflammatory agents and, for example:
. arylpropionic derivatives such as ketoprofen, ibuprofen, naproxen, flurbiprofen, alminoprofen, tiaprofenic acid, arylacetic derivatives such as diclofenac, fentiazac, arylcarboxylic derivatives such as fenbufen and etodolac, anthranilic derivatives or fenamates such as niflumic acid and mefenamic acid, . indole derivatives such as indometacin and oxametacin, oxicams such as piroxicam, tenoxicam, pyrazole-containing derivatives such as phenylbutazone, indene derivatives such as sulindac;
- steroidal anti-inflammatory agents such as corticoids of the prednisone, prednisolone and methylprednisolone type;
- antibiotics of the beta-lactam type, such as penicillins, of the cephalosporin type, such as cefuroxime axetil, of the beta-lactamase inhibitor type, such as clavulanic acid, of the aminoglycoside type, such as neomycin, of the macrolide type, such as spiramycin, erythromycin, of the tetracycline type, such as minocycline and doxycycline, of th.e sulfamide type, such as sulfadiazine, of the quinolone type, such as pefloxacin;
- antituberculous agents such as isoniazid, rifampicin, ethambutol, pyrazinamide;
SUBSTITUTE SHEET (RULE 26) - polyenic antifungal agents such as amphotericin B, nystatin, -- imidazole-containing antifungal agents such as miconazole, ketoconazole, fluconazole, flucytosine, griseofulvin;
- antiviral agents of the type including zidovudine, aciclovir, adamantane such as rimantadine, amantadine, and moroxydine;
- beta-blockers such as acebutolol, celiprolol, atenolol, betaxolol, metoprolol, bisoprolol, propanolol, nadolol, timolol, tertatolol, sotalol, pindolol, penbutolol, carteolol, oxyprenolol, labetalol;
- nitrated derivatives such as isosorbide dinitrate, isosorbide mononitrate, pentaerythrityl tetranitrate, erythrityl tetranitrate;
- antianginals of the sydnonimine type, such as molsidomine and linsidomine, - cardiotonics such as orciprenaline, or alternatively of the digitalin type, such as digoxin, digitoxin, - diuretics such as furosemide, bumetanide, clopamide, of the thiazide type such as hydrochlorothiazide, xipamide, of the tienilic acid type, indapamide, cicletanine, spironolactone, canrenone, amiloride, triamteren;
- conversion enzyme inhibitors such as captopril, enalapril, lisinopril, perindopril, quinalapril, ramipril, benazepril;
- calcium inhibitors such as nifedipinu, nicardipine, nitrendipine, diltiazem, verapamil, bepridil;
- antihypertensives such as rilmenidine, clonidine, methyldopa, dihydralazine, prasozine, uradipil, minoxidil;
- antiarrhythmics such as quinidine, disopyramide, cibenzoline, propafenone, flecainide, aprindine, nadoxolol, mexiletine, bretylium, amiodarone;
- antiischaemics such as naftidrofuryl, trimetazidine, pentoxyfilline, nicergoline, buflomedil, dihydroergotoxine, dihydroergocristine, SUBSTtTUTE SHEET (RULE 26) dihydroergocryptine, moxisylyte, raubasine, vincamine, papaverine, nicotinic acid;
- venotonics such as vitamin P;
- hypotension correctors such as heptaminol;
- hormones such as thyroid hormones of the levothyroxine sodium type;
- medicaments stimulating gastroduodenal motor function,, such as cisapride, domperidone;
- antiemetics such as metoclopramide, metopimazine, aliprazide, odansetron, scopolamine;
- antiulcer agents such as ranitidine, famotidine, nizatidine, cimetidine, omeprazole, of the antiulcer prostaglandin type such as misoprostol, sucralfate, aluminium hydroxide;
- antidiarrhoeals such as loperamide, diphenoxylate, medicaments promoting bacterial flora and those promoting yeast flora;
- intestinal antiseptics such as nitrofuran;
- contraceptives such as oestroprogestogens;
- antianaemic agents such as iron;
- antihistaminics such as phenothiazine;
- vitamins such as thiamine, nicotinamide, pyridoxine, biotin, ascorbic acid, cyanocobalamine, retinol, colecalciferol;
- antiepileptics such as vaiproic acid, phenytoin, carbamazepine, ethosuximide, progabide, vigabatrin;
- antimigraine agents such as oxetorone, indoramine, ergotamine, ergot of rye derivatives such as dihydroergotamine, methysergide, tricyclic derivatives such as pizotifen;
- anticoagulants such as antivitamin K agents;
- antiparkinsonians such as levodopa, selegiline, lisuride, bromocriptine, biperiden, orphenadrine, procyclidine, tropatepin, scopolamine;
- anxiolytics derived from benzodiazepines such as clotiazepam, tofisopam, oxazepam, alprazolam, lorazepam, bromazepam, prazepam, buspirone, alpidem, hydroxyzine, meprobamate, febarbamate;
SUBSTlTUTE SHEET (RULE 26) - antidepressants such as quinupramine, desipramine, imipramine, clomipramine, amitriptyline, viloxazine, amineptine, fluvoxamine, fluoxetine, tianeptine, oxaflozane, maprotiline, mianserin, trazodone, medifoxamine, toloxatone, IMAOs;
- hypnotics such as zopiclone, zolpidem, and benzodiazepine derivatives such as flunitrazepam, nitrazepam, triazolam, phenotiazine derivatives such as niaprazine, doxylamine, barbiturate derivatives such as butobarbital, amobarbital, phenobarbital;
- normothymics such as lithium, valpromide;
- neuroleptics such as thioxanthen, pimozide, loxapine, carpipramine, phenothiazine derivatives such as chlorpromazine, thioridazine, fluphenazine, butyrophenone derivatives such as haloperidol, penfluridol, pipamperone, benperidol, benzamide derivatives such as sulpiride, amisulpiride, tiapride, sultopride;
- antimetabolites such as methotrexate, mercaptopurine, fluorouracil, cytarabine, hydroxo-urea, asparaginase;
- alkylating agents such as busulfan, pipobroman, procarbazine, nitrogen mustard derivatives such as chiorambucil, cyclophosphamide, estramustine, melphalan, lomustine, fotemustine;
- anticancer steroids such as methoxyprogesterone, gestonorone, norethisterone, diethylstilbestrol, dienestrol;
- and more generally peptides having a therapeutic activity.
A pharmaceutically acceptable salt of any one of the salifiable active ingredients listed above may also be selected as active ingredient.
The content of active ingredient in the first layer will be determined according to the pathology to be treated.
This content may be high, it being possible for the active substance to represent up to 99.0% of the total weight of the first layer, and for example from 1 SUBSTITUTE SHEET (RULE 26) WO 99534aS Pcr/EP98/08100 to 99.0% by weight, preferably from 85 to 95% of the total weight of the first layer.
The second layer may contain up to 98.5% by weight of active ingredient, for example from 1 to 95%
by weight, better still from 60 to 80%.
Numerous immediate-release compositions are known in the art and persons skilled in the art may thereby be freely inspired for the production of the first layer.
Persons skilled in the art will choose in particular the constituents of the first layer so as to ensure rapid disintegration thereof upon contact with water or with a physiological fluids.
It is in particular known to incorporate into this type of layer a disintegrating agent whose role is to cause the disintegration of the tablet in the presence of water or of physiological fluids.
These disintegrating agents are normally included in the said layer in an amount of from 0 to 15% by weight, preferably from 2 to 5% by weight.
Examples of such disintegrating agents are: alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, anhydrous colloidal silica, croscarmellose sodium, crospovidone, guar gum, magnesium and aluminium silicate, methyl cellulose, microcrystalline cellulose, potassium polacrilin, cellulose, pregelatinized starch, sodium alginate, starch sodium glycolate, starch and the effervescent mixtures known in the art for their disintegrating action.
The effervescent mixtures form part of the substances capable of rapidly causing the disintegration of the first layer, especially when the latter comes into contact with the gastric acids. These mixtures generally contain alkali metal or alkaline-earth metal carbonates or bicarbonates or sodium glycine carbonate.
Other additives may be incorporated into the immediate-release layer, such as diluents, binders, SUBSTITUTE SHEET (RULE 26) WO 99l33448 PCf/EP98i08100 - ?0 -lubricants, antioxidants, colourings, sweeteners, flavourings and acidulants, wetting agents, hydrophilizing agents such as sorbitol and cyclodextrins, osmotic agents such as mannitol, pH
correctors, stabilizing agents such as trehalose and mannitol, adsorbants, chelating and sequestering agents and gastroresistant film-coating excipients of the type including cellulose acetylphthalate and polymethacrylates.
By way of example, there may be chosen any one of the following diluents or alternatively a combination thereof: calcium carbonate, calcium sulfate, sucrose., dextrates, dextrin, dextrose, dicalcium phosphate dihydrate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, cellulose, microcrystalline cellulose, sorbitol, starches, pregelatinized starch, talc, tricalcium phosphate and lactose.
Among the binders, there may be mentioned: gum arabic, gum tragacanth, guar gum, alginic acid, sodium alginate, sodium carboxymethylcellulose, dextrin, gelatin, hydroxyethylcellulose, hydroxypropylcellulose, liquid glucose, magnesium and aluminium silicate, maltodextrin, povidone, pregelatinized starch, starch and zein.
The lubricants are glidants (such as anhydrous colloidal silica, magnesium trisilicate, magnesium silicate, cellulose, starch, talc or tricalcium phosphate) or alternatively antifriction adhering agents (such as calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated vegetable oils, paraffin, magnesium stearate, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, fumaric acid, stearic acid or zinc stearate and talc).
As examples of antioxidants, persons skilled in the art may select any of the following compounds:
ascorbic acid, ascorbyl palmitate, fumaric acid, propyl SUBSTIIUTE SHEET (RULE 26) WO 99/33448 PCf/EP98/08100 gallate, sodium ascorbate and sodium metabisulfite, alpha-tocopherol, malic acid, BHA and BTH.
Preferred wetting agents are:
- sodium docusate and sodium lauryl sulfate which are anionic surfactants;
- benzalkonium chloride, benzethonium chloride and cetrimide which are cationic surfactants;
- glyceryl monooleate, fatty acid esters of polyoxyethylene sorbitan, poly(vinyl alcohol) and sorbitans, which are nonionic surfactants.
Among the pH regulators, there are acidifying agents of the type including citric acid, hydrochloric acid, lactic acid, tartaric acid, as well as alkalinizing agents of the type including monoethanolamine, diethanolamine and triethanolamine, potassium citrate, sodium bicarbonate, sodium citrate dihydrate.
Examples of adsorbents are bentonite, anhydrous colloidal silica, kaolin, magnesium and aluminium silicate, microcrystalline cellulose and cellulose.
As chelating and sequestering agents, there may be used citric acid monohydrate, edetic acid, disodium phosphate, monosodium phosphate, potassium citrate, tartaric acid and sodium citrate dihydrate.
The quantities of these additives are those normally used in the art. Generally, the binder may represent from 0.5 to 25% by weight, better still from 2 to 5% by weight of the said first layer.
The lubricants are preferably incorporated into this first layer in an amount of 0.01 to 10% by weight.
As a guide, the quantity of gastroresistant film-coating excipients varies between 0.5 and 9% by weight.
It will be noted that all the abovementioned additives, with the exception of the disintegrating agents may also be added to the prolonged-release layer in similar proportions. The prolonged-release layer may, in addition, contain diluents chosen from glyceryl palmitostearate, hydrogenated vegetable oils, SUBSTITUTE SHEET (RULE 26) _ 12 -polymethacrylates, potassium chloride and sodium chloride.
Moreover, binders such as carbomer, ethyl cellulose, hydrogenated vegetable oils, hydroxypropylmethylcellulose, methyl cellulose and polymethacrylates may be incorporated into the prolonged-release layer.
However, the essential constituents of the second prolonged-release layer are polymeric materials which confer on it its inert and nonbiodegradable character. According to the invention, the polymeric materials in question are polymers or copolymers insoluble in water (but not forming a gel either upon immersion in an aqueous medium) which are discharged intact by the body.
These polymers may play the role of binder in the composition of the second layer.
Such materials are in particular polyvinyl chlorides, vinyl acetate/vinyl chloride copolymers, acrylonitrile/vinylidene chloride copolymers, polydimethylsiloxanes and copolymers derived from (meth)acrylic acids.
The copolymers derived from (meth)acrylic acids comprise the copolymers of derivatives of methacrylic acid and the copolymers of derivatives of acrylic acid and of derivatives of methacrylic acid. As derivatives of (meth)acrylic acids, esters are preferred.
According to a preferred embodiment of the invention, the nonbiodegradable inzrt polymeric material is chosen from the groups consisting of ethyl acrylate and methyl methacrylate copolymers, ethylammonium methacrylate and methyl acrylate copolymers, ethylammonium methacrylate and ethyl acrylate copolymers, ethylammonium methacrylate and methyl methacrylate copolymers, ethylammonium methacrylate and ethyl methacrylate copolymers, methacrylic acid and ethyl acrylate copolymers, methacrylic acid and methyl methacrylate copolymers.
SUBSTITUTE SHEET (RULE 26) According to the invention, "ethylammonium" is understood to mean a radical chosen from the ammonioethyl, (C1-C4)alkylammonioethyl, di(C1-C4)alkyl-ammonioethyl and tri(Cl-C9)alkylammonioethyl groups.
Preferably, ethylammonium designates a trimethyl-ammonioethyl radical.
Such materials are commercially available, for example, from the company RtShm.
There may be mentioned, purely as a guide:
- the copolymers Eudragit RL 30 D , Eudragit RS 30 D , Eudragit RL P0 and Eudragit RS PO , Eudragit RL 12.5 , Eudragit RS 12.5 , Eudragit RL 100' and Eudragit RS 100 , which are copolymers of esters of acrylic acid and of esters of methacrylic acid, with a low content of ammonium groups. These polymers have as recurring unit:
?=O ?=O
H2 + CH3 CH2N~CH3 Ci_ CH3 in which R1 is a hydrogen atom or a methyl group and R2 is the methyl or ethyl group;
- the copolymer Eudragit NE 30 D which is a neutral copolymer of ethyl acrylate and methyl methacrylate, in which the recurring unit has the formula:
._..C HZ-7 H-C Hr-i-...
=0O -0 CjCZH3 OCH3 SUBSTITUTE SHEET (RULE 26) - the copolymers Eudragit L 30 D-55 and Eudragit L100-55 which are copolymers of methacrylic acid and ethyl acrylate, in which the recurring unit has the formula:
... --C HT-c -c A~O A-O
dH bC2Hs - the copolymers Eudragit L 100 , Eudragit L 12.5 , Eudragit S 100 and Eudragit S 12.5 which are copolymers of methacrylic acid and methyl methacrylate in which the recurring unit has the formula:
.. .--C --C HI--~
7s0 7~O
Among these polymers, the copolymer NE 30 D
has proved particularly advantageous. In general, the copolymers of esters of methacrylic acid and of esters of acrylic acid are used in preference to any other type of inert matrix.
The molecular mass of the polymeric material used may vary to a large extent depending on the nature of the monomers constituting the material.
In the case of the copolymers derived from acrylic and/or methacrylic acid mentioned above, the average molecular mass is between 100,000 and 1,000,000, preferably between 130,000 and 800,000.
It is desirable that the quantity of inert polymeric materials does not exceed 25% of the total weight of the second layer, and is not less than 1% of the total weight of this layer. Preferably, the SUBSTITUTE SHEET (RULE 26) quantity of polymeric materials varies between 2.5% and 12$ of the total weight of the second layer.
The whole tablet may be coated with a gastroresistant or enterosoluble polymeric film, such that the active ingredient is released only in the duodenal tract.
The polymeric substances generally used for the production of the gastroresistant systems are cellulose acetophthalate, cellulose acetopropionate, cellulose trimellitate or polymers and copolymers of (meth)acrylic acids.
The tablets of the invention are conventionally prepared by a method including the steps of granulation,.followed by compression.
More precisely, the method of preparation, which is the subject of the invention, comprises the steps consisting in:
a) preparing a granule of a first active substance from a pulverulent mixture of the said first active substance, a disintegrating agent and one or more additives suitable for the preparation of a layer for the immediate release of the said active substance;
b) preparing a granule of a second active substance from a pulverulent mixture of the said second active substance, from one or more nonbiodegradable inert polymeric materials and from one or more additives suitable for the preparation of a layer for the prolonged release of the said active substance;
c) combining, by compressing, irl a manner known per se, the two types of granule obtained in steps a) and b) above so as to obtain tablets in which the first layer, affording immediate release, results from the compression of the granule obtained in step a), and, having a second layer arranged in contact with the said first layer, the said second layer resulting from the compression of the prolonged-release granule obtained in step b).
The first step (step a)) is designed to provide a granule based on the first active substance, which SUBSTITUTE SHEET (RULE 26) will lead, through compression, to the first layer, called immediate-release layer.
The second step (step b)) is designed to provide a granule based on the same active substance or on a different active substance, which will lead, through compression, to the second layer,. called prolonged-release layer. The constituents of this layer are those of the nonbiodegradable inert polymeric matrix defined above.
Step c) leads to the formation of the tablet through successive compression of the granules obtained in the preceding steps a) and b).
Steps a) and b) involve the granulation of powders of amorphous or crystallized particles. This granulation is carried out in a manner known per se and, for example, by a wet granulation method.
The method of granulation comprises five essential steps: (i) dry-mixing of its various constituents, (ii) wetting, (iii) granulation proper, (iv) drying, and then (v) sizing.
The dry-mixing consists in mixing the pulverulent excipients entering into the composition of the granule.
The wetting consists in adding to the pulverulent mixture various constituents, a wettirig liquid which may be water, a(C1-C4) alkanol, an aqueous solution of binder or an alcoholic solution of binder.
According to the invention, the expression "alcoholic solution of binder" includes both the alcoholic and aqueous-alcoholic solutions in which the solvent is a mixture of one or more (C1-C4)alkanols or a mixture of water and of one or more (Cl-C4)alkanols. A preferred (C1-Cq)alkanol is isopropanol. It is carried out in a kneading, planetary, mixing pan, projection or whirling-type mixer-blender or a rapid-type mixer-granulator.
In step a), the appropriate wetting liquid is water, a(C1-C4)alkanol, an aqueous solution of binder SUBSTITUTE SHEET (RULE 26) or an alcoholic solution of binder as defined above, and as generally recommended in the art.
In step b), it is possible to use an aqueous dispersion or an organic solution of the nonbiodegradable polymeric material(s) as wetting liquid. Better homogeneity of distribution. of the matrix is thus obtained. "Organic solution" is understood according to the invention to mean a solution of the nonbiodegradable polymeric material(s) in an organic solvent which is either a mixture of one or more (Ci-C4)alkanols, or a mixture of one or more ((C1-C9) alkyl) ((C1-Cq) alkyl) ketones and of one or more (C1-C4)alkanols. According to the invention, isopropanol is the preferred (Ci-C4)alkanol. Likewise, when a mixture of ketone(s) and of alkanol(s) is used, the mixture of isopropanol and acetone is preferred.
When the polymeric material is a copolymer derived from acrylic and/or methacrylic acid, the dispersion or the solution will preferably have a viscosity of between 10 and 300 mPa.s, better still between 15 and 200 mPa.s.
According to a preferred embodiment of the invention, the sizing is carried out by passing over a screen with a mesh opening of between 0.5 and 1.5 mm, preferably of between 0.8 and 1.5 mm.
The preferred value of the mesh opening is 1.25 mm in each of steps a) and b).
However, the invention is not limited to carrying out a wet granulation method. Thus, persons skilled in the art will also be able to use the other existing granulation methods, such as the dry granulation method.
The last step (step c) ) leads to the formation of the tablet. The combination of the granules is carried'out in a conventional manner using the granules obtained in steps a) and b).
In the case of bilayer tablets, containing concentric layers, this step involves (i) compression, in a first compression chamber, of the entire SUBSTITUTE SHEET (RULE 26) prolonged-release granule obtained in step b) for the production of a core tablet; (ii) the compression, in a second compression chamber, of a portion, preferably 50% by weight, of the immediate-release granule obtained in step a) above; (iii) the introduction and the positioning of the core tablet resulting from step (i) above in the said second compression chamber;
(iv) the application of a gentle compression with centring of the core in the said second compression chamber; (v) the addition of the remainder of the immediate-release granule to the said second granulation chamber; and (vi) the conjoint compression of the immediate-release granule on the tablet formed in step iv) above.
In the case of bilayer tablets, containing parallel layers, step c) comprises: (i) a gentle compression of the entire prolonged-release granule in a compression chamber; and then (ii) the addition of the entire immediate-release granule to the said compression chamber and its positioning on the tablet resulting from step i) above; and (iii) the final compression of the tablet.
The respective proportions of the immediate-release and prolonged-release granules are not critical according to the invention.
The tablets of the invention may be administered by the oral or vaginal route. They allow the immediate release of a first active substance, and, then the release of a second active substance, which is optionally identical to the first, over a period of 2 to 12 h.
The multilayer tablets of the invention are particularly advantageous since their method of preparation is simple, the excipients constituting them being customary. Furthermore, it is possible, by appropriately selecting the nonbiodegradable inert polymeric materials, to vary the dissolution profiles to a very large extent and with precision, depending on the needs.
SUBSTITUTE SHEET (RULE 26) According to the preferred embodiment of the invention, the polymeric materials belong to the Eudragit series marketed by the company RtShm, which are copolymers derived from methacrylic and/or acrylic acid. Because of the diversity of the properties of these copolymers, it is possible to obtain modulation of the release profile of the active ingredients.
In addition, these copolymers confer on the resulting tablets excellent formulation capacity (possibility of incorporating high levels of active ingredients) and compression capacity.
The choice of such copolymers offers, in addition, the possibility of film-coating the tablets with excipients of the Eudragit type in order to obtain a gastroresistant coating.
On the other hand, these copolymers are absolutely inert in relation to the body, which ensures release of the active ingredient independently of the influence of the body (and in particular of pH
variations) and therefore reliability, safety, quality, reproducibility and better tolerance of the effects linked to the administration of the tablets of the invention.
The examples provided in the text which follows illustrate the invention more clearly. Reference will be made to the accompanying Figures 1 and 2.
$XAMPLE 1 a) Preparation and formulrtioa of the immadiat=-ralaaae granul=
The active ingredient is 2-ethoxymethyl-4(3H)-pteridinone, designated as EMP in the text which follows.
The constituents for the preparation of the immediate-release granule, designated as GLI-1 in the text which follows, were used in the following proportions by weight:
EMP - 94.12%
Polyvinylpyrrolidone 30 2.94%
SUBSTITUTE SHEET (RULE 26) Cross-linked carboxymethylcellulose 2.94$
Total 100.00%
The active ingredient, polyvinylpyrrolidone 30, and the carboxymethylcellulose are introduced into a mixer-granulator for a 3-minute mixing.
The wetting liquid, osmosed water, is then introduced into the mixer-granulator until well-formed grains and agglomerates are obtained. Next, the whole is dried (oven or fluidized air bed) and sized on a screen with a mesh opening of 1.25 mm.
b) Praparation and formulation of tha prolonqtd-releaae granula The active ingredient is that used in Example 1.
The nonbiodegradable polymeric material used is Eudragit NE 30 D marketed by the company RtShm.
The constituents for the preparation of the prolonged-release granule, designated as GLP-1 in the text which follows, were used in the following proportions by weight:
EMP 71.70%
Fine lactose powder 17.20%
Eudragit NE 30D 8.80%
Talc 1.10%
Magnesium stearate 1.20%
Total 100.00%
The active ingredient and the lactose are introduced into a mixer-granulator for a 3-minute mixing.
The Eudragit NE 30 D , which is an aqueous dispersion of a neutral copolymer of ethyl acrylate and methyl methacrylate, is then gradually introduced into the mixture, as wetting liquid. Purified water is added, if necessary, in order to obtain well-formed granules comprising agglomerates. Next, the granule is dried in a fluidized air bed and sized on a screen with a mesh opening of 1.25 mm. The lubricants (talc and SUBSTITUTE SHEET (RULE 26) magnesium stearate) are then mixed with the granule obtained above for 40 seconds.
c) Preparation of tablets coataiaing coaceatric layers and of so-called tablets contaiaing parallel layers The following tablets containing parallel layers A to D are obtained using the following steps by means of a compressing machine provided with ovoid dies:
(i) by gentle compression, in a compression chamber, of the entire prolonged-release granule of Example ib); and (ii) by addition, in the same compression chamber, of the entire immediate-release granule of Example la) over the tablet obtained in step (i); and (iii) by subsequent compression of the whole consisting of the immediate-release granule of Example la) and of the tablet obtained in step (i) above.
The following tablet containing concentric layers E was obtained using the following steps:
(a) the compression, in a first compression chamber, of the entire prolonged-release granule of Example ib) for the production of a core tablet;
(b) the compression of a fraction of the immediate-release granule of Example la) in a second compression chamber (about half);
(c) the transfer of the tablet resulting from step (a) into the second compression chamber;
(d) the application of a gentle compression with centring of the tablet of step (a) in the said second compression chamber;
(e) the addition of the remainder of the immediate-release granule of Example la) to the second compression chamber, and (f) the conjoint compression of the immediate-release granule of Example la) and of the tablet resulting from step (d) above.
Table 1 below indicates, for each tablet, the respective quantities of granules used.
SUBSTITUTE SHEET (RULE 26) Tablet Quantity of Quantity of Unit weight (reference) GLI granules GLP granules of the tablet (mg) (mg) (mg) A 425.0 558.0 983.0 B 531.2 697.5 1228.7 C 318.7 976.3 1295.0 D 318.7 697.5 1016.2 E 531.2 558.0 1089.2 Dissolution profiles for the tabl ts manufacturad according to tha procedur4 of Example 1 The dissolution profiles for the tablets manufactured in the preceding example were determined by UV spectrometry.
The tablet to be,tested is introduced into a reactor previously charged with one litre of osmosed water, at 37 C, and provided with a temperature-regulating system and with an effective stirring system.
During the whole experiment, the reactor is kept stirring at 37 C.
At regular intervals of time t, samples of the medium contained in the reactor are collected, filtered on a filter with a porosity of 0.45 pm, and analysed by UV spectrometry.
Conditions for analysis by UV spwctromstry:
The optical density of the samples collected, diluted in a known volume of osmosed warer,.is measured at 313 nm.
The quantity of active ingredient q present in the sample is determined by comparison with the optical density of a control solution of the active ingredient, EMP, of known concentration. A simple calculation makes it possible to find the total quantity of active ingredient released in the reactor.at the instant t.
The dissolution profile for a tablet tested is obtained by plotting, on a curve, the calculated SUBSTITUTE SHEET (RULE 26) quantities of active ingredient as a function of the time of collection.
The accompanying Figures 1 and 2 show the dissolution profiles plotted in the cases of tablets A
to E above.
By following the operating protocol described in Example 1, the tablets containing parallel layers F
to I in the following Table 2 are prepared:
,Type of Quantity of Type of Quantity of Tablet immediate- immediate- prolonged prolonged-release release -release release granules granules (mg) granules granules (mg) F GLI-2 327.9 GLP-2 836.8 G GLI-2 546.4 GLP-3 697.35 H GLI-2 327.9 GLP-4 697.35 I GLI-2 437.15 GLP-4 557.9 The formulation of the immediate-release granules, GLI-2, is given below:
EMP 91.5%
Polyvinylpyrrolidone 30 4.0%
Cross-linked carboxymethylcellulose 4.0$
Magnesium stearate 0.5%
TOTAL 100%
These granules are prepared using the operating protocol of Example la).
The formulations of the prolonged-release granules are given below:
EMP 71.7%
Fine lactose powder 16%
Eudragit RSPO 10%
Talc 1.1%
Magnesium stearate 1.2%
TOTAL 100%
SUBSTITUTE SHEET (RULE 26) EMP 71.7%
Fine lactose powder 17.2%
Eudragit RS30D 8.8%
Talc 1.1%
Magnesium stearate 1.2%
TOTAL 100%
EMP 71.7%
Fine lactose powder 17.2%
Eudragit RSPO 8.8%
Talc 1.1%
Magnesium stearate 1.2%
TOTAL 100%
These granules are prepared using the operating protocol of Example ib).
The dissolution curves for tablets F to I were plotted using the operating protocol described in Example 2.
These curves are presented in Figures 3 to 6.
SUBSTITUTE SHEET (RULE 26)
The invention relates to solid galenic forms of the controlled release tablet type for the instant and then prolonged release of one or more active substances.
The importance of such galenic forms is undeniable. The immediate release of an active substance will ensure its practically instant bioavailability, which is particularly desirable in the case of patients suffering from acute conditions.
However, in the case of active substances having a short half-life, the therapeutic activity is only temporary. Now, a continuous and regular supply of active ingredient is often necessary for an effective therapy. To this end, numerous immediate- and prolonged-release systems have been developed.
Reference may be made, for example, to the following patents and applications of the state of the art: WO 96/03111, US 4,990,335, EP 352 190, BE 905 282, EP 106 443, EP 36 350, EP 615 444 and EP 220 670.
However, in the prior art systems, the kinetics of release of the active ingredient depend on many factors, such as the enzymatic activity and the pH
conditions which vary substantially from one individual to another and for the same individual, depending on whether they are on an empty stomach or not.
Furthermore, the pH conditions vary all along the gastrointestinal tract. Thus, it is difficult to predict in vivo, with precision, the profile for the release of a given substance after administration of the prior art instant- and prolonged-release systems.
The present invention aims to solve this problem by providing tablets which preserve their characteristics for the release of active substances regardless of the conditions of administration in vivo SUBSTtTUTE SHEET (RULE 26) _ 2 _ The tablets of the invention provide an excellent reproducibility of the results, while allowing an increased control of the rates of release during the phase of prolonged release of the active ingredient. By using the tablets of the invention, it becomes possible to optimize the supply of the active ingredients in the body while taking into account both the subject's tolerance to the active ingredient and the pharmacokinetic and metabolic profiles of the active ingredient.
Tablets of the invention are, moreover, advantageous from the point of view of the formulation of the active ingredients since a judicious choice of the excipients leads to tablets with high concentrations of active ingredients.
Thus, it is possible to produce tablets with very high doses, having an acceptable size for oral administration.
More precisely, the invention relates to multilayer tablets for the instant and then prolonged release of active substances comprising at least two superposed layers, characterized in that:
- a first outer layer is composed of a mixture .of excipients and of a first active substance, the said first layer allowing immediate release of the said first active substance;
- a second layer, arranged in contact with the said first layer, consists of a nonbiodegradable, inert porous polymeric matrix in which a second active substance is dispersed.
The second layer, which is arranged in contact with the first layer, is either completely enveloped by the first layer, or only partially covered by it.
In the first case, the two layers are concentric.
In the second case, only one of the surfaces of the second layer is in contact with the first layer: in the text which follows, this type of tablet is designated as "containing parallel layers" and the SUBSTITUTE SHEET (RULE 26) shape of the tablet is unimportant and is in particular ovoidal. It should be understood that in this case, the two layers have one outer surface, their other surface being in contact with one another.
The tablets of the invention are preferably bilayered. However, the invention also encompasses multilayer tablets, as long as they comprise the combination of the first and second layers defined above.
For some active ingredients, problems of stability of the active ingredient included in the prolonged-release matrix may exist. In this case, it is advantageous to opt for the preparation of tablets containing concentric layers.
The kinetics of release of the active ingredient depend, in each case, on the exact composition of the layer considered. It is by adapting the nature and the quantity of the excipients constituting the two layers that the kinetics of release can be modulated.
One characteristic of the first layer is that it disintegrates rapidly at the site of administration.
In contrast, the second layer is not biodegradable. Its matrix is inert in the sense that it does not react with the surrounding medium. The matrix of the second layer retains its physical and chemical integrity throughout the prolonged release of the active ingredient, regardless of the pH variations.
Since the first layer disintegrates instantly upon contact with an aqueous medium such as a physiological medium, it is easy to understand why the release of the first active substance is immediate.
In the case of the second layer and since the matrix constituting it is inert (it does not become eroded and does not swell in an aqueous medium), the release of the second active substance occurs by lixiviation and diffusion. The surrounding aqueous medium gradually penetrates into the inert porous matrix and then progressively, this aqueous medium SUBSTITUTE SHEET (RULE 26) dissolves the active substance dispersed in the inert matrix. The mechanism of diffusion being slow in essence, it can be understood why the release of the active ingredient is prolonged in this case.
Whereas the mechanism of disintegration of the first layer does not, or not to any great extent, depend on the nature of the active substance, it is clear that the more or less hydrophilic character of the active substance of the second layer can influence the kinetics of lixiviation/diffusion.
However, the invention is not limited as to the nature of the active substances. Each layer may contain a different active ingredient.
However, according to a specific embodiment of the invention, the first and second layers comprise the same active substance.
The active substances may be chosen in particular from any of the following groups (to designate the active substances, the international nonproprietary names have been adopted):
- medicaments which are active in asthma such as 2-ethoxymethyl-4(3H)-pteridinone and bronchodilators such as theophylline, and/or some anti-inflammatory agents or antihistaminics of the ketotifen type;
- medicaments which are active in the treatment of diabetes and its related complications of the neurological, nephrological, ocular or vascular type.
By way of example, there may be mentioned metformin, hypolipidaemic agents such as fenofibrate or pravastatin and anti-atheromatous agents in general;
- medicaments which are active in the treatment of alcoholism, such as acamprosate;
- peripheral analgesics, for example para-aminophenol derivatives such as paracetamol, salicylated derivatives such as aspirin, diflunisal, propionic acid derivatives such as ibuprofen, fenoprofen, ketoprofen, aminoquinoline derivatives such as floctafenine, pyrazolone derivatives such as noramidopyrine;
SUBS'TITUTE SHEET (RULE 26) - central analgesics such as dextropoxyphene, codeine, morphine, pethidine, dextromoramide, buprenorphine, nalbuphine, pentazocine;
- antispasmodics such as tiemonium, difemerine, phloroglucinol, trimebutine, pinaveriunn, prifinium;
- nonsteroidal anti-inflammatory agents and, for example:
. arylpropionic derivatives such as ketoprofen, ibuprofen, naproxen, flurbiprofen, alminoprofen, tiaprofenic acid, arylacetic derivatives such as diclofenac, fentiazac, arylcarboxylic derivatives such as fenbufen and etodolac, anthranilic derivatives or fenamates such as niflumic acid and mefenamic acid, . indole derivatives such as indometacin and oxametacin, oxicams such as piroxicam, tenoxicam, pyrazole-containing derivatives such as phenylbutazone, indene derivatives such as sulindac;
- steroidal anti-inflammatory agents such as corticoids of the prednisone, prednisolone and methylprednisolone type;
- antibiotics of the beta-lactam type, such as penicillins, of the cephalosporin type, such as cefuroxime axetil, of the beta-lactamase inhibitor type, such as clavulanic acid, of the aminoglycoside type, such as neomycin, of the macrolide type, such as spiramycin, erythromycin, of the tetracycline type, such as minocycline and doxycycline, of th.e sulfamide type, such as sulfadiazine, of the quinolone type, such as pefloxacin;
- antituberculous agents such as isoniazid, rifampicin, ethambutol, pyrazinamide;
SUBSTITUTE SHEET (RULE 26) - polyenic antifungal agents such as amphotericin B, nystatin, -- imidazole-containing antifungal agents such as miconazole, ketoconazole, fluconazole, flucytosine, griseofulvin;
- antiviral agents of the type including zidovudine, aciclovir, adamantane such as rimantadine, amantadine, and moroxydine;
- beta-blockers such as acebutolol, celiprolol, atenolol, betaxolol, metoprolol, bisoprolol, propanolol, nadolol, timolol, tertatolol, sotalol, pindolol, penbutolol, carteolol, oxyprenolol, labetalol;
- nitrated derivatives such as isosorbide dinitrate, isosorbide mononitrate, pentaerythrityl tetranitrate, erythrityl tetranitrate;
- antianginals of the sydnonimine type, such as molsidomine and linsidomine, - cardiotonics such as orciprenaline, or alternatively of the digitalin type, such as digoxin, digitoxin, - diuretics such as furosemide, bumetanide, clopamide, of the thiazide type such as hydrochlorothiazide, xipamide, of the tienilic acid type, indapamide, cicletanine, spironolactone, canrenone, amiloride, triamteren;
- conversion enzyme inhibitors such as captopril, enalapril, lisinopril, perindopril, quinalapril, ramipril, benazepril;
- calcium inhibitors such as nifedipinu, nicardipine, nitrendipine, diltiazem, verapamil, bepridil;
- antihypertensives such as rilmenidine, clonidine, methyldopa, dihydralazine, prasozine, uradipil, minoxidil;
- antiarrhythmics such as quinidine, disopyramide, cibenzoline, propafenone, flecainide, aprindine, nadoxolol, mexiletine, bretylium, amiodarone;
- antiischaemics such as naftidrofuryl, trimetazidine, pentoxyfilline, nicergoline, buflomedil, dihydroergotoxine, dihydroergocristine, SUBSTtTUTE SHEET (RULE 26) dihydroergocryptine, moxisylyte, raubasine, vincamine, papaverine, nicotinic acid;
- venotonics such as vitamin P;
- hypotension correctors such as heptaminol;
- hormones such as thyroid hormones of the levothyroxine sodium type;
- medicaments stimulating gastroduodenal motor function,, such as cisapride, domperidone;
- antiemetics such as metoclopramide, metopimazine, aliprazide, odansetron, scopolamine;
- antiulcer agents such as ranitidine, famotidine, nizatidine, cimetidine, omeprazole, of the antiulcer prostaglandin type such as misoprostol, sucralfate, aluminium hydroxide;
- antidiarrhoeals such as loperamide, diphenoxylate, medicaments promoting bacterial flora and those promoting yeast flora;
- intestinal antiseptics such as nitrofuran;
- contraceptives such as oestroprogestogens;
- antianaemic agents such as iron;
- antihistaminics such as phenothiazine;
- vitamins such as thiamine, nicotinamide, pyridoxine, biotin, ascorbic acid, cyanocobalamine, retinol, colecalciferol;
- antiepileptics such as vaiproic acid, phenytoin, carbamazepine, ethosuximide, progabide, vigabatrin;
- antimigraine agents such as oxetorone, indoramine, ergotamine, ergot of rye derivatives such as dihydroergotamine, methysergide, tricyclic derivatives such as pizotifen;
- anticoagulants such as antivitamin K agents;
- antiparkinsonians such as levodopa, selegiline, lisuride, bromocriptine, biperiden, orphenadrine, procyclidine, tropatepin, scopolamine;
- anxiolytics derived from benzodiazepines such as clotiazepam, tofisopam, oxazepam, alprazolam, lorazepam, bromazepam, prazepam, buspirone, alpidem, hydroxyzine, meprobamate, febarbamate;
SUBSTlTUTE SHEET (RULE 26) - antidepressants such as quinupramine, desipramine, imipramine, clomipramine, amitriptyline, viloxazine, amineptine, fluvoxamine, fluoxetine, tianeptine, oxaflozane, maprotiline, mianserin, trazodone, medifoxamine, toloxatone, IMAOs;
- hypnotics such as zopiclone, zolpidem, and benzodiazepine derivatives such as flunitrazepam, nitrazepam, triazolam, phenotiazine derivatives such as niaprazine, doxylamine, barbiturate derivatives such as butobarbital, amobarbital, phenobarbital;
- normothymics such as lithium, valpromide;
- neuroleptics such as thioxanthen, pimozide, loxapine, carpipramine, phenothiazine derivatives such as chlorpromazine, thioridazine, fluphenazine, butyrophenone derivatives such as haloperidol, penfluridol, pipamperone, benperidol, benzamide derivatives such as sulpiride, amisulpiride, tiapride, sultopride;
- antimetabolites such as methotrexate, mercaptopurine, fluorouracil, cytarabine, hydroxo-urea, asparaginase;
- alkylating agents such as busulfan, pipobroman, procarbazine, nitrogen mustard derivatives such as chiorambucil, cyclophosphamide, estramustine, melphalan, lomustine, fotemustine;
- anticancer steroids such as methoxyprogesterone, gestonorone, norethisterone, diethylstilbestrol, dienestrol;
- and more generally peptides having a therapeutic activity.
A pharmaceutically acceptable salt of any one of the salifiable active ingredients listed above may also be selected as active ingredient.
The content of active ingredient in the first layer will be determined according to the pathology to be treated.
This content may be high, it being possible for the active substance to represent up to 99.0% of the total weight of the first layer, and for example from 1 SUBSTITUTE SHEET (RULE 26) WO 99534aS Pcr/EP98/08100 to 99.0% by weight, preferably from 85 to 95% of the total weight of the first layer.
The second layer may contain up to 98.5% by weight of active ingredient, for example from 1 to 95%
by weight, better still from 60 to 80%.
Numerous immediate-release compositions are known in the art and persons skilled in the art may thereby be freely inspired for the production of the first layer.
Persons skilled in the art will choose in particular the constituents of the first layer so as to ensure rapid disintegration thereof upon contact with water or with a physiological fluids.
It is in particular known to incorporate into this type of layer a disintegrating agent whose role is to cause the disintegration of the tablet in the presence of water or of physiological fluids.
These disintegrating agents are normally included in the said layer in an amount of from 0 to 15% by weight, preferably from 2 to 5% by weight.
Examples of such disintegrating agents are: alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, anhydrous colloidal silica, croscarmellose sodium, crospovidone, guar gum, magnesium and aluminium silicate, methyl cellulose, microcrystalline cellulose, potassium polacrilin, cellulose, pregelatinized starch, sodium alginate, starch sodium glycolate, starch and the effervescent mixtures known in the art for their disintegrating action.
The effervescent mixtures form part of the substances capable of rapidly causing the disintegration of the first layer, especially when the latter comes into contact with the gastric acids. These mixtures generally contain alkali metal or alkaline-earth metal carbonates or bicarbonates or sodium glycine carbonate.
Other additives may be incorporated into the immediate-release layer, such as diluents, binders, SUBSTITUTE SHEET (RULE 26) WO 99l33448 PCf/EP98i08100 - ?0 -lubricants, antioxidants, colourings, sweeteners, flavourings and acidulants, wetting agents, hydrophilizing agents such as sorbitol and cyclodextrins, osmotic agents such as mannitol, pH
correctors, stabilizing agents such as trehalose and mannitol, adsorbants, chelating and sequestering agents and gastroresistant film-coating excipients of the type including cellulose acetylphthalate and polymethacrylates.
By way of example, there may be chosen any one of the following diluents or alternatively a combination thereof: calcium carbonate, calcium sulfate, sucrose., dextrates, dextrin, dextrose, dicalcium phosphate dihydrate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, cellulose, microcrystalline cellulose, sorbitol, starches, pregelatinized starch, talc, tricalcium phosphate and lactose.
Among the binders, there may be mentioned: gum arabic, gum tragacanth, guar gum, alginic acid, sodium alginate, sodium carboxymethylcellulose, dextrin, gelatin, hydroxyethylcellulose, hydroxypropylcellulose, liquid glucose, magnesium and aluminium silicate, maltodextrin, povidone, pregelatinized starch, starch and zein.
The lubricants are glidants (such as anhydrous colloidal silica, magnesium trisilicate, magnesium silicate, cellulose, starch, talc or tricalcium phosphate) or alternatively antifriction adhering agents (such as calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated vegetable oils, paraffin, magnesium stearate, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, fumaric acid, stearic acid or zinc stearate and talc).
As examples of antioxidants, persons skilled in the art may select any of the following compounds:
ascorbic acid, ascorbyl palmitate, fumaric acid, propyl SUBSTIIUTE SHEET (RULE 26) WO 99/33448 PCf/EP98/08100 gallate, sodium ascorbate and sodium metabisulfite, alpha-tocopherol, malic acid, BHA and BTH.
Preferred wetting agents are:
- sodium docusate and sodium lauryl sulfate which are anionic surfactants;
- benzalkonium chloride, benzethonium chloride and cetrimide which are cationic surfactants;
- glyceryl monooleate, fatty acid esters of polyoxyethylene sorbitan, poly(vinyl alcohol) and sorbitans, which are nonionic surfactants.
Among the pH regulators, there are acidifying agents of the type including citric acid, hydrochloric acid, lactic acid, tartaric acid, as well as alkalinizing agents of the type including monoethanolamine, diethanolamine and triethanolamine, potassium citrate, sodium bicarbonate, sodium citrate dihydrate.
Examples of adsorbents are bentonite, anhydrous colloidal silica, kaolin, magnesium and aluminium silicate, microcrystalline cellulose and cellulose.
As chelating and sequestering agents, there may be used citric acid monohydrate, edetic acid, disodium phosphate, monosodium phosphate, potassium citrate, tartaric acid and sodium citrate dihydrate.
The quantities of these additives are those normally used in the art. Generally, the binder may represent from 0.5 to 25% by weight, better still from 2 to 5% by weight of the said first layer.
The lubricants are preferably incorporated into this first layer in an amount of 0.01 to 10% by weight.
As a guide, the quantity of gastroresistant film-coating excipients varies between 0.5 and 9% by weight.
It will be noted that all the abovementioned additives, with the exception of the disintegrating agents may also be added to the prolonged-release layer in similar proportions. The prolonged-release layer may, in addition, contain diluents chosen from glyceryl palmitostearate, hydrogenated vegetable oils, SUBSTITUTE SHEET (RULE 26) _ 12 -polymethacrylates, potassium chloride and sodium chloride.
Moreover, binders such as carbomer, ethyl cellulose, hydrogenated vegetable oils, hydroxypropylmethylcellulose, methyl cellulose and polymethacrylates may be incorporated into the prolonged-release layer.
However, the essential constituents of the second prolonged-release layer are polymeric materials which confer on it its inert and nonbiodegradable character. According to the invention, the polymeric materials in question are polymers or copolymers insoluble in water (but not forming a gel either upon immersion in an aqueous medium) which are discharged intact by the body.
These polymers may play the role of binder in the composition of the second layer.
Such materials are in particular polyvinyl chlorides, vinyl acetate/vinyl chloride copolymers, acrylonitrile/vinylidene chloride copolymers, polydimethylsiloxanes and copolymers derived from (meth)acrylic acids.
The copolymers derived from (meth)acrylic acids comprise the copolymers of derivatives of methacrylic acid and the copolymers of derivatives of acrylic acid and of derivatives of methacrylic acid. As derivatives of (meth)acrylic acids, esters are preferred.
According to a preferred embodiment of the invention, the nonbiodegradable inzrt polymeric material is chosen from the groups consisting of ethyl acrylate and methyl methacrylate copolymers, ethylammonium methacrylate and methyl acrylate copolymers, ethylammonium methacrylate and ethyl acrylate copolymers, ethylammonium methacrylate and methyl methacrylate copolymers, ethylammonium methacrylate and ethyl methacrylate copolymers, methacrylic acid and ethyl acrylate copolymers, methacrylic acid and methyl methacrylate copolymers.
SUBSTITUTE SHEET (RULE 26) According to the invention, "ethylammonium" is understood to mean a radical chosen from the ammonioethyl, (C1-C4)alkylammonioethyl, di(C1-C4)alkyl-ammonioethyl and tri(Cl-C9)alkylammonioethyl groups.
Preferably, ethylammonium designates a trimethyl-ammonioethyl radical.
Such materials are commercially available, for example, from the company RtShm.
There may be mentioned, purely as a guide:
- the copolymers Eudragit RL 30 D , Eudragit RS 30 D , Eudragit RL P0 and Eudragit RS PO , Eudragit RL 12.5 , Eudragit RS 12.5 , Eudragit RL 100' and Eudragit RS 100 , which are copolymers of esters of acrylic acid and of esters of methacrylic acid, with a low content of ammonium groups. These polymers have as recurring unit:
?=O ?=O
H2 + CH3 CH2N~CH3 Ci_ CH3 in which R1 is a hydrogen atom or a methyl group and R2 is the methyl or ethyl group;
- the copolymer Eudragit NE 30 D which is a neutral copolymer of ethyl acrylate and methyl methacrylate, in which the recurring unit has the formula:
._..C HZ-7 H-C Hr-i-...
=0O -0 CjCZH3 OCH3 SUBSTITUTE SHEET (RULE 26) - the copolymers Eudragit L 30 D-55 and Eudragit L100-55 which are copolymers of methacrylic acid and ethyl acrylate, in which the recurring unit has the formula:
... --C HT-c -c A~O A-O
dH bC2Hs - the copolymers Eudragit L 100 , Eudragit L 12.5 , Eudragit S 100 and Eudragit S 12.5 which are copolymers of methacrylic acid and methyl methacrylate in which the recurring unit has the formula:
.. .--C --C HI--~
7s0 7~O
Among these polymers, the copolymer NE 30 D
has proved particularly advantageous. In general, the copolymers of esters of methacrylic acid and of esters of acrylic acid are used in preference to any other type of inert matrix.
The molecular mass of the polymeric material used may vary to a large extent depending on the nature of the monomers constituting the material.
In the case of the copolymers derived from acrylic and/or methacrylic acid mentioned above, the average molecular mass is between 100,000 and 1,000,000, preferably between 130,000 and 800,000.
It is desirable that the quantity of inert polymeric materials does not exceed 25% of the total weight of the second layer, and is not less than 1% of the total weight of this layer. Preferably, the SUBSTITUTE SHEET (RULE 26) quantity of polymeric materials varies between 2.5% and 12$ of the total weight of the second layer.
The whole tablet may be coated with a gastroresistant or enterosoluble polymeric film, such that the active ingredient is released only in the duodenal tract.
The polymeric substances generally used for the production of the gastroresistant systems are cellulose acetophthalate, cellulose acetopropionate, cellulose trimellitate or polymers and copolymers of (meth)acrylic acids.
The tablets of the invention are conventionally prepared by a method including the steps of granulation,.followed by compression.
More precisely, the method of preparation, which is the subject of the invention, comprises the steps consisting in:
a) preparing a granule of a first active substance from a pulverulent mixture of the said first active substance, a disintegrating agent and one or more additives suitable for the preparation of a layer for the immediate release of the said active substance;
b) preparing a granule of a second active substance from a pulverulent mixture of the said second active substance, from one or more nonbiodegradable inert polymeric materials and from one or more additives suitable for the preparation of a layer for the prolonged release of the said active substance;
c) combining, by compressing, irl a manner known per se, the two types of granule obtained in steps a) and b) above so as to obtain tablets in which the first layer, affording immediate release, results from the compression of the granule obtained in step a), and, having a second layer arranged in contact with the said first layer, the said second layer resulting from the compression of the prolonged-release granule obtained in step b).
The first step (step a)) is designed to provide a granule based on the first active substance, which SUBSTITUTE SHEET (RULE 26) will lead, through compression, to the first layer, called immediate-release layer.
The second step (step b)) is designed to provide a granule based on the same active substance or on a different active substance, which will lead, through compression, to the second layer,. called prolonged-release layer. The constituents of this layer are those of the nonbiodegradable inert polymeric matrix defined above.
Step c) leads to the formation of the tablet through successive compression of the granules obtained in the preceding steps a) and b).
Steps a) and b) involve the granulation of powders of amorphous or crystallized particles. This granulation is carried out in a manner known per se and, for example, by a wet granulation method.
The method of granulation comprises five essential steps: (i) dry-mixing of its various constituents, (ii) wetting, (iii) granulation proper, (iv) drying, and then (v) sizing.
The dry-mixing consists in mixing the pulverulent excipients entering into the composition of the granule.
The wetting consists in adding to the pulverulent mixture various constituents, a wettirig liquid which may be water, a(C1-C4) alkanol, an aqueous solution of binder or an alcoholic solution of binder.
According to the invention, the expression "alcoholic solution of binder" includes both the alcoholic and aqueous-alcoholic solutions in which the solvent is a mixture of one or more (C1-C4)alkanols or a mixture of water and of one or more (Cl-C4)alkanols. A preferred (C1-Cq)alkanol is isopropanol. It is carried out in a kneading, planetary, mixing pan, projection or whirling-type mixer-blender or a rapid-type mixer-granulator.
In step a), the appropriate wetting liquid is water, a(C1-C4)alkanol, an aqueous solution of binder SUBSTITUTE SHEET (RULE 26) or an alcoholic solution of binder as defined above, and as generally recommended in the art.
In step b), it is possible to use an aqueous dispersion or an organic solution of the nonbiodegradable polymeric material(s) as wetting liquid. Better homogeneity of distribution. of the matrix is thus obtained. "Organic solution" is understood according to the invention to mean a solution of the nonbiodegradable polymeric material(s) in an organic solvent which is either a mixture of one or more (Ci-C4)alkanols, or a mixture of one or more ((C1-C9) alkyl) ((C1-Cq) alkyl) ketones and of one or more (C1-C4)alkanols. According to the invention, isopropanol is the preferred (Ci-C4)alkanol. Likewise, when a mixture of ketone(s) and of alkanol(s) is used, the mixture of isopropanol and acetone is preferred.
When the polymeric material is a copolymer derived from acrylic and/or methacrylic acid, the dispersion or the solution will preferably have a viscosity of between 10 and 300 mPa.s, better still between 15 and 200 mPa.s.
According to a preferred embodiment of the invention, the sizing is carried out by passing over a screen with a mesh opening of between 0.5 and 1.5 mm, preferably of between 0.8 and 1.5 mm.
The preferred value of the mesh opening is 1.25 mm in each of steps a) and b).
However, the invention is not limited to carrying out a wet granulation method. Thus, persons skilled in the art will also be able to use the other existing granulation methods, such as the dry granulation method.
The last step (step c) ) leads to the formation of the tablet. The combination of the granules is carried'out in a conventional manner using the granules obtained in steps a) and b).
In the case of bilayer tablets, containing concentric layers, this step involves (i) compression, in a first compression chamber, of the entire SUBSTITUTE SHEET (RULE 26) prolonged-release granule obtained in step b) for the production of a core tablet; (ii) the compression, in a second compression chamber, of a portion, preferably 50% by weight, of the immediate-release granule obtained in step a) above; (iii) the introduction and the positioning of the core tablet resulting from step (i) above in the said second compression chamber;
(iv) the application of a gentle compression with centring of the core in the said second compression chamber; (v) the addition of the remainder of the immediate-release granule to the said second granulation chamber; and (vi) the conjoint compression of the immediate-release granule on the tablet formed in step iv) above.
In the case of bilayer tablets, containing parallel layers, step c) comprises: (i) a gentle compression of the entire prolonged-release granule in a compression chamber; and then (ii) the addition of the entire immediate-release granule to the said compression chamber and its positioning on the tablet resulting from step i) above; and (iii) the final compression of the tablet.
The respective proportions of the immediate-release and prolonged-release granules are not critical according to the invention.
The tablets of the invention may be administered by the oral or vaginal route. They allow the immediate release of a first active substance, and, then the release of a second active substance, which is optionally identical to the first, over a period of 2 to 12 h.
The multilayer tablets of the invention are particularly advantageous since their method of preparation is simple, the excipients constituting them being customary. Furthermore, it is possible, by appropriately selecting the nonbiodegradable inert polymeric materials, to vary the dissolution profiles to a very large extent and with precision, depending on the needs.
SUBSTITUTE SHEET (RULE 26) According to the preferred embodiment of the invention, the polymeric materials belong to the Eudragit series marketed by the company RtShm, which are copolymers derived from methacrylic and/or acrylic acid. Because of the diversity of the properties of these copolymers, it is possible to obtain modulation of the release profile of the active ingredients.
In addition, these copolymers confer on the resulting tablets excellent formulation capacity (possibility of incorporating high levels of active ingredients) and compression capacity.
The choice of such copolymers offers, in addition, the possibility of film-coating the tablets with excipients of the Eudragit type in order to obtain a gastroresistant coating.
On the other hand, these copolymers are absolutely inert in relation to the body, which ensures release of the active ingredient independently of the influence of the body (and in particular of pH
variations) and therefore reliability, safety, quality, reproducibility and better tolerance of the effects linked to the administration of the tablets of the invention.
The examples provided in the text which follows illustrate the invention more clearly. Reference will be made to the accompanying Figures 1 and 2.
$XAMPLE 1 a) Preparation and formulrtioa of the immadiat=-ralaaae granul=
The active ingredient is 2-ethoxymethyl-4(3H)-pteridinone, designated as EMP in the text which follows.
The constituents for the preparation of the immediate-release granule, designated as GLI-1 in the text which follows, were used in the following proportions by weight:
EMP - 94.12%
Polyvinylpyrrolidone 30 2.94%
SUBSTITUTE SHEET (RULE 26) Cross-linked carboxymethylcellulose 2.94$
Total 100.00%
The active ingredient, polyvinylpyrrolidone 30, and the carboxymethylcellulose are introduced into a mixer-granulator for a 3-minute mixing.
The wetting liquid, osmosed water, is then introduced into the mixer-granulator until well-formed grains and agglomerates are obtained. Next, the whole is dried (oven or fluidized air bed) and sized on a screen with a mesh opening of 1.25 mm.
b) Praparation and formulation of tha prolonqtd-releaae granula The active ingredient is that used in Example 1.
The nonbiodegradable polymeric material used is Eudragit NE 30 D marketed by the company RtShm.
The constituents for the preparation of the prolonged-release granule, designated as GLP-1 in the text which follows, were used in the following proportions by weight:
EMP 71.70%
Fine lactose powder 17.20%
Eudragit NE 30D 8.80%
Talc 1.10%
Magnesium stearate 1.20%
Total 100.00%
The active ingredient and the lactose are introduced into a mixer-granulator for a 3-minute mixing.
The Eudragit NE 30 D , which is an aqueous dispersion of a neutral copolymer of ethyl acrylate and methyl methacrylate, is then gradually introduced into the mixture, as wetting liquid. Purified water is added, if necessary, in order to obtain well-formed granules comprising agglomerates. Next, the granule is dried in a fluidized air bed and sized on a screen with a mesh opening of 1.25 mm. The lubricants (talc and SUBSTITUTE SHEET (RULE 26) magnesium stearate) are then mixed with the granule obtained above for 40 seconds.
c) Preparation of tablets coataiaing coaceatric layers and of so-called tablets contaiaing parallel layers The following tablets containing parallel layers A to D are obtained using the following steps by means of a compressing machine provided with ovoid dies:
(i) by gentle compression, in a compression chamber, of the entire prolonged-release granule of Example ib); and (ii) by addition, in the same compression chamber, of the entire immediate-release granule of Example la) over the tablet obtained in step (i); and (iii) by subsequent compression of the whole consisting of the immediate-release granule of Example la) and of the tablet obtained in step (i) above.
The following tablet containing concentric layers E was obtained using the following steps:
(a) the compression, in a first compression chamber, of the entire prolonged-release granule of Example ib) for the production of a core tablet;
(b) the compression of a fraction of the immediate-release granule of Example la) in a second compression chamber (about half);
(c) the transfer of the tablet resulting from step (a) into the second compression chamber;
(d) the application of a gentle compression with centring of the tablet of step (a) in the said second compression chamber;
(e) the addition of the remainder of the immediate-release granule of Example la) to the second compression chamber, and (f) the conjoint compression of the immediate-release granule of Example la) and of the tablet resulting from step (d) above.
Table 1 below indicates, for each tablet, the respective quantities of granules used.
SUBSTITUTE SHEET (RULE 26) Tablet Quantity of Quantity of Unit weight (reference) GLI granules GLP granules of the tablet (mg) (mg) (mg) A 425.0 558.0 983.0 B 531.2 697.5 1228.7 C 318.7 976.3 1295.0 D 318.7 697.5 1016.2 E 531.2 558.0 1089.2 Dissolution profiles for the tabl ts manufacturad according to tha procedur4 of Example 1 The dissolution profiles for the tablets manufactured in the preceding example were determined by UV spectrometry.
The tablet to be,tested is introduced into a reactor previously charged with one litre of osmosed water, at 37 C, and provided with a temperature-regulating system and with an effective stirring system.
During the whole experiment, the reactor is kept stirring at 37 C.
At regular intervals of time t, samples of the medium contained in the reactor are collected, filtered on a filter with a porosity of 0.45 pm, and analysed by UV spectrometry.
Conditions for analysis by UV spwctromstry:
The optical density of the samples collected, diluted in a known volume of osmosed warer,.is measured at 313 nm.
The quantity of active ingredient q present in the sample is determined by comparison with the optical density of a control solution of the active ingredient, EMP, of known concentration. A simple calculation makes it possible to find the total quantity of active ingredient released in the reactor.at the instant t.
The dissolution profile for a tablet tested is obtained by plotting, on a curve, the calculated SUBSTITUTE SHEET (RULE 26) quantities of active ingredient as a function of the time of collection.
The accompanying Figures 1 and 2 show the dissolution profiles plotted in the cases of tablets A
to E above.
By following the operating protocol described in Example 1, the tablets containing parallel layers F
to I in the following Table 2 are prepared:
,Type of Quantity of Type of Quantity of Tablet immediate- immediate- prolonged prolonged-release release -release release granules granules (mg) granules granules (mg) F GLI-2 327.9 GLP-2 836.8 G GLI-2 546.4 GLP-3 697.35 H GLI-2 327.9 GLP-4 697.35 I GLI-2 437.15 GLP-4 557.9 The formulation of the immediate-release granules, GLI-2, is given below:
EMP 91.5%
Polyvinylpyrrolidone 30 4.0%
Cross-linked carboxymethylcellulose 4.0$
Magnesium stearate 0.5%
TOTAL 100%
These granules are prepared using the operating protocol of Example la).
The formulations of the prolonged-release granules are given below:
EMP 71.7%
Fine lactose powder 16%
Eudragit RSPO 10%
Talc 1.1%
Magnesium stearate 1.2%
TOTAL 100%
SUBSTITUTE SHEET (RULE 26) EMP 71.7%
Fine lactose powder 17.2%
Eudragit RS30D 8.8%
Talc 1.1%
Magnesium stearate 1.2%
TOTAL 100%
EMP 71.7%
Fine lactose powder 17.2%
Eudragit RSPO 8.8%
Talc 1.1%
Magnesium stearate 1.2%
TOTAL 100%
These granules are prepared using the operating protocol of Example ib).
The dissolution curves for tablets F to I were plotted using the operating protocol described in Example 2.
These curves are presented in Figures 3 to 6.
SUBSTITUTE SHEET (RULE 26)
Claims (12)
1. Multilayer tablet for the instant and then prolonged release of active substances comprising at least two superposed layers, wherein:
a first outer layer is composed of a mixture of excipients and of a first active substance, the first layer allowing immediate release of the first active substance;
a second layer, arranged in contact with the first layer, consists of a nonbiodegradable, inert porous polymeric matrix in which a second active substance is dispersed.
a first outer layer is composed of a mixture of excipients and of a first active substance, the first layer allowing immediate release of the first active substance;
a second layer, arranged in contact with the first layer, consists of a nonbiodegradable, inert porous polymeric matrix in which a second active substance is dispersed.
2. Tablet according to claim 1, wherein the second active substance is identical to the first active substance.
3. Tablet according to claim 1 or 2, wherein the nonbiodegradable inert polymeric matrix contains one or more nonbiodegradable inert polymeric materials chosen from polyvinyl chlorides, vinyl acetate/vinyl chloride copolymers, copolymers derived from acrylic and/or methacrylic acids, acrylonitrile/vinylidene chloride copolymers and polydimethylsiloxanes.
4. Tablet according to claim 3, wherein the copolymers derived from methacrylic and/or acrylic acids are chosen from the groups consisting of copolymers of esters of ethyl acrylate and methyl methacrylate, ethylammonium methacrylate and methyl acrylate copolymers, ethylammonium methacrylate and ethyl acrylate copolymers, ethylammonium methacrylate and methyl methacrylate copolymers, ethylammonium methacrylate and ethyl methacrylate copolymers, methacrylic acid and ethyl acrylate copolymers, methacrylic acid and methyl methacrylate copolymers.
5. Tablet according to claim 3 or 4, wherein the nonbiodegradable inert polymeric materials are present in the second layer in an amount of 1 to 25% by weight.
6. Tablet according to any one of claims 1 to 5, wherein the porous polymeric matrix comprises from 1 to 95%
by weight of the second active substance.
by weight of the second active substance.
7. Tablet according to any one of claims 1 to 6, wherein the first layer comprises one or more disintegrating agents chosen from alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, anhydrous colloidal silica, croscarmellose sodium, crospovidone, guar gum, magnesium and aluminium silicate, methyl cellulose, microcrystalline cellulose, potassium polacrilin, cellulose, pregelatinized starch, sodium alginate, starch sodium glycolate, starch and the effervescent mixtures known in the art for their disintegrating action.
8. Tablet according to any one of claims 1 to 7, wherein the first layer comprises from 1 to 99.0% by weight of the first active substance.
9. Bilayer tablet according to any one of claims 1 to 8, wherein the second layer has a top surface and a bottom surface, only one of the surfaces being in contact with the first layer.
10. Bilayer tablet according to any one of claims 1 to 9, wherein the first layer and the second layer are concentric.
11. Method for preparing a tablet according to any one of claims 1 to 10, comprising the steps consisting in:
a) preparing a granule of a first active substance from a pulverulent mixture of the first active substance, a disintegrating agent and one or more additives suitable for the preparation of a layer for the immediate release of the active substance;
b) preparing a granule of a second active substance from a pulverulent mixture of the second active substance, from one or more nonbiodegradable inert polymeric materials and from one or more additives suitable for the preparation of a layer for the prolonged release of the active substance;
c) combining, by compressing, in a manner known per se, the two types of granule obtained in steps a) and b) above so as to obtain tablets in which the first layer, affording immediate release, results from the compression of the granule obtained in step a), and, having a second layer arranged in contact with the first layer, the second layer resulting from the compression of the granule obtained in step b).
a) preparing a granule of a first active substance from a pulverulent mixture of the first active substance, a disintegrating agent and one or more additives suitable for the preparation of a layer for the immediate release of the active substance;
b) preparing a granule of a second active substance from a pulverulent mixture of the second active substance, from one or more nonbiodegradable inert polymeric materials and from one or more additives suitable for the preparation of a layer for the prolonged release of the active substance;
c) combining, by compressing, in a manner known per se, the two types of granule obtained in steps a) and b) above so as to obtain tablets in which the first layer, affording immediate release, results from the compression of the granule obtained in step a), and, having a second layer arranged in contact with the first layer, the second layer resulting from the compression of the granule obtained in step b).
12. Tablet according to any one of claims 1 to 10, wherein the second layer comprises, as active substance, 2-ethoxymethyl-4(3H)-pteridinone.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR97/16402 | 1997-12-23 | ||
| FR9716402A FR2772615B1 (en) | 1997-12-23 | 1997-12-23 | MULTILAYER TABLET FOR INSTANT RELEASE THEN PROLONGED ACTIVE SUBSTANCES |
| PCT/EP1998/008100 WO1999033448A1 (en) | 1997-12-23 | 1998-12-11 | Tablet for instant and prolonged release of one or more active substances |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2316277A1 CA2316277A1 (en) | 1999-07-08 |
| CA2316277C true CA2316277C (en) | 2008-07-08 |
Family
ID=9515042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002316277A Expired - Fee Related CA2316277C (en) | 1997-12-23 | 1998-12-11 | Tablet for instant and prolonged release of one or more active substances |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6372255B1 (en) |
| EP (1) | EP1041972B1 (en) |
| JP (1) | JP4451563B2 (en) |
| KR (1) | KR100574207B1 (en) |
| CN (1) | CN1163220C (en) |
| AR (1) | AR017897A1 (en) |
| AT (1) | ATE223207T1 (en) |
| AU (1) | AU743195B2 (en) |
| BR (1) | BR9814345A (en) |
| CA (1) | CA2316277C (en) |
| CZ (1) | CZ291884B6 (en) |
| DE (1) | DE69807747T2 (en) |
| DK (1) | DK1041972T3 (en) |
| ES (1) | ES2182397T3 (en) |
| FR (1) | FR2772615B1 (en) |
| HU (1) | HU226069B1 (en) |
| ID (1) | ID26313A (en) |
| NO (1) | NO20003289L (en) |
| PT (1) | PT1041972E (en) |
| RU (1) | RU2212885C2 (en) |
| SK (1) | SK283236B6 (en) |
| UA (1) | UA55503C2 (en) |
| WO (1) | WO1999033448A1 (en) |
| ZA (1) | ZA9811799B (en) |
Families Citing this family (158)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9407386D0 (en) | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
| US20030109503A1 (en) * | 1995-06-06 | 2003-06-12 | Smithkline Beecham P.L.C. | Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics |
| US8022095B2 (en) * | 1996-08-16 | 2011-09-20 | Pozen, Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
| DE19821625C1 (en) * | 1998-05-15 | 2000-01-05 | Merck Patent Gmbh | Pharmaceutical preparation |
| EP1005863A1 (en) * | 1998-12-04 | 2000-06-07 | Synthelabo | Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof |
| US6294199B1 (en) | 1999-04-13 | 2001-09-25 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising administering amoxycillin |
| US6878386B1 (en) | 1999-04-13 | 2005-04-12 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate |
| US7250176B1 (en) * | 1999-04-13 | 2007-07-31 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection |
| EP1064937A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| WO2001013901A2 (en) * | 1999-08-20 | 2001-03-01 | Ferrosan A/S | A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress |
| CA2383212C (en) * | 1999-09-02 | 2008-11-25 | Nostrum Pharmaceuticals, Inc. | Controlled release oral dosage suitable for oral administration |
| NZ518052A (en) * | 1999-09-28 | 2005-04-29 | Panacea Biotec Ltd | Controlled release compositions comprising nimesulide (4-nitro-2-phenoxymethanesulfonanilide) for a once-a-day oral dosage to treat diseases such as arthritis |
| BR0007360A (en) * | 1999-12-23 | 2001-08-14 | Johnson & Johnson | Controlled release composition |
| EP1138330A1 (en) * | 1999-12-23 | 2001-10-04 | Warner-Lambert Company | Combination of trimebutine with an opioid analgesic |
| ES2270982T3 (en) * | 2000-02-04 | 2007-04-16 | Depomed, Inc. | DOSAGE FORM OF NUCLEO AND CARCASA THAT IS APPROXIMATE TO A RELEASE OF THE ZERO ORDER PHARMACO. |
| US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
| US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
| US20070141107A1 (en) * | 2000-03-15 | 2007-06-21 | Orbusneich Medical, Inc. | Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device |
| US6372252B1 (en) * | 2000-04-28 | 2002-04-16 | Adams Laboratories, Inc. | Guaifenesin sustained release formulation and tablets |
| EP1330236A2 (en) | 2000-10-12 | 2003-07-30 | Beecham Pharmaceuticals (Pte) Limited | Formulation containing amoxicillin |
| US6756057B2 (en) | 2000-10-12 | 2004-06-29 | Beecham Pharmaceuticals (Pte) Limited | Amoxicillin and potassium clavulanate dosage form |
| EP1330250B1 (en) * | 2000-10-30 | 2004-05-12 | Lupin Limited | Rapidly disintegrating sustained release cefuroxime axetil composition |
| KR100778835B1 (en) * | 2000-12-28 | 2007-11-22 | 엘지.필립스 엘시디 주식회사 | Method of Manufacturing of Liquid Crystal Display |
| KR100685945B1 (en) | 2000-12-29 | 2007-02-23 | 엘지.필립스 엘시디 주식회사 | Liquid crystal display and manufacturing method of the same |
| US20030032675A1 (en) * | 2001-02-15 | 2003-02-13 | Franz G. Andrew | Manufacture of thyroid hormone tablets having consistent active moiety amounts |
| US20030224047A1 (en) * | 2001-02-15 | 2003-12-04 | Franz G. Andrew | Levothyroxine compositions and methods |
| EP1365745A2 (en) * | 2001-02-15 | 2003-12-03 | King Pharmaceuticals, Inc. | Stabilized pharmaceutical and thyroid hormone compositions and method of preparation |
| US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
| NZ529308A (en) * | 2001-04-05 | 2005-03-24 | Collagenex Pharm Inc | Tetracycline compounds comprising a tetracycline and a controlled release agent to provide delivery at a dose below that required for antibiotic activity |
| CA2343949A1 (en) * | 2001-04-12 | 2002-10-12 | Bernard Charles Sherman | Benazepril hydrochloride tablet formulations |
| SE0101379D0 (en) | 2001-04-18 | 2001-04-18 | Diabact Ab | Composition that inhibits gastric acid secretion |
| US20030035839A1 (en) * | 2001-05-15 | 2003-02-20 | Peirce Management, Llc | Pharmaceutical composition for both intraoral and oral administration |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| GB0114069D0 (en) * | 2001-06-08 | 2001-08-01 | Smithkline Beecham Plc | Composition |
| US20030190349A1 (en) * | 2001-08-10 | 2003-10-09 | Franz G. Andrew | Methods of stabilizing pharmaceutical compositions |
| US20030198667A1 (en) * | 2001-08-10 | 2003-10-23 | Franz Andrew G. | Methods of producing dispersible pharmaceutical compositions |
| US20030198671A1 (en) * | 2001-08-10 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique plasma AUC properties |
| US20030180353A1 (en) * | 2001-08-10 | 2003-09-25 | Franz G. Andrew | Stabilized pharmaceutical compositions |
| US20030203967A1 (en) * | 2001-08-14 | 2003-10-30 | Franz G. Andrew | Levothyroxine compositions having unique Tmax properties |
| US20030199586A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Unique levothyroxine aqueous materials |
| US20030199587A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique Cmax properties |
| US20030195253A1 (en) * | 2001-08-14 | 2003-10-16 | Franz G. Andrew | Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration |
| US20030198672A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique triidothyronine plasma AUC properties |
| US20030181524A1 (en) * | 2001-10-29 | 2003-09-25 | Franz G. Andrew | Levothyroxine compositions having unique triiodothyronine Tmax properties |
| US6645526B2 (en) * | 2001-11-13 | 2003-11-11 | Mylan Pharmaceuticals, Inc. | Storage stable thyroxine active drug formulations and methods for their production |
| US20030099699A1 (en) * | 2001-11-13 | 2003-05-29 | Hanshew Dwight D. | Storage stable thyroxine active drug formulations and methods for their production |
| US6863901B2 (en) | 2001-11-30 | 2005-03-08 | Collegium Pharmaceutical, Inc. | Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration |
| US6827946B2 (en) | 2001-12-05 | 2004-12-07 | Collegium Pharmaceutical, Inc. | Compositions containing both sedative and non-sedative antihistamines |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| US7229644B2 (en) * | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
| WO2003105809A1 (en) | 2002-06-17 | 2003-12-24 | Themis Laboratories Private Limited | Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them |
| PA8578501A1 (en) | 2002-07-25 | 2005-02-04 | Pharmacia Corp | DOSAGE FORM ONCE A DAY OF PRAMIPEXOL |
| AR040588A1 (en) * | 2002-07-26 | 2005-04-13 | Schering Corp | PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE |
| US20040116532A1 (en) * | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
| KR101363679B1 (en) * | 2002-09-20 | 2014-02-14 | 안드렉스 랩스 엘엘씨 | Pharmaceutical tablet |
| SE0203065D0 (en) * | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
| TWI319713B (en) * | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
| US8487002B2 (en) * | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
| MXPA02010828A (en) * | 2002-11-04 | 2004-07-16 | Leopoldo Espinosa Abdala | Pharmaceutical composition in capsules comprising a non-steroidal anti-inflammatory and an opiate analgesic for handling pain. |
| US20040115265A1 (en) * | 2002-12-11 | 2004-06-17 | Loutfy Benkerrour | Multilayered tablet containing pravastatin and aspirin and method |
| US20040253311A1 (en) * | 2002-12-18 | 2004-12-16 | Roger Berlin | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines |
| AU2003303631B2 (en) * | 2002-12-26 | 2008-05-29 | Nuvo Pharmaceuticals (Ireland) Designated Activity Company | Multilayer Dosage Forms Containing NSAIDs and Triptans |
| TWI355276B (en) * | 2003-01-14 | 2012-01-01 | Akira Tsuji | Gastrointestinal absorption enhancer mediated by p |
| CA2554012A1 (en) * | 2003-01-21 | 2004-08-05 | Smartrix Technologies Inc. | Oral dosage formulation |
| DE602004015246D1 (en) * | 2003-02-11 | 2008-09-04 | Alza Corp | METHOD AND DOSAGE FORMS WITH MODIFIED LAYERING GEOMETRY |
| FR2851734B1 (en) * | 2003-02-28 | 2006-06-09 | Galenix Innovations | PROCESS FOR THE PRODUCTION OF A PHARMACEUTICAL COMPOSITION IN THE FORM OF TABLETS CONTAINING A FIBRATE AND COMPRESSES OBTAINED BY THE PROCESS |
| MXPA05009886A (en) * | 2003-03-14 | 2006-05-04 | Nirmal Mulye | A process for preparing sustained release tablets. |
| US20040192781A1 (en) * | 2003-03-31 | 2004-09-30 | Haley Eugene T. | Method of administration for metoclopramide and pharmaceutical formulation therefor |
| US7749532B2 (en) * | 2003-04-07 | 2010-07-06 | Supernus Pharmaceuticals, Inc. | Once daily formulations of tetracyclines |
| US20050013863A1 (en) * | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
| US6863830B1 (en) * | 2003-08-21 | 2005-03-08 | Biolab Services, Inc. | Dual layer tablet, method of making and use thereof |
| US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
| US20050118267A1 (en) * | 2003-09-19 | 2005-06-02 | Penwest Pharmaceuticals Co. | Chronotherapeutic dosage forms |
| MXPA06003450A (en) | 2003-09-26 | 2006-08-31 | Johnson & Johnson | Drug coating providing high drug loading and methods for providing the same. |
| WO2005030166A1 (en) * | 2003-09-26 | 2005-04-07 | Alza Corporation | Oros push-stick for controlled delivery of active agents |
| US20060172006A1 (en) * | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
| US20050084531A1 (en) * | 2003-10-16 | 2005-04-21 | Jatin Desai | Tablet with aqueous-based sustained release coating |
| EP1715852A2 (en) * | 2004-01-06 | 2006-11-02 | Panacea Biotec Ltd. | Non-disintegrating oral solid composition of high dose of water soluble drugs |
| US20050226929A1 (en) * | 2004-04-12 | 2005-10-13 | Jianbo Xie | Controlled release opioid analgesic formulation |
| WO2005099672A1 (en) * | 2004-04-13 | 2005-10-27 | Ranbaxy Laboratories Limited | A modified release pharmaceutical formulation comprising amoxicillin and clavulanate |
| SI1591109T1 (en) * | 2004-04-30 | 2008-10-31 | Topotarget Germany Ag | Formulation comprising histone deacetylase inhibitor exhibiting biphasic release |
| FR2873113B1 (en) * | 2004-07-19 | 2007-06-15 | Eurotab Sa | COMPACT SOLID BILOUCHE PRODUCT FOR WATER PURIFICATION |
| US20060020007A1 (en) * | 2004-07-26 | 2006-01-26 | Roger Berlin | Compositions containing policosanol and biotin and their pharmaceutical uses |
| RS51527B2 (en) * | 2004-08-13 | 2018-02-28 | Boehringer Ingelheim Int | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| US9326959B2 (en) | 2004-09-01 | 2016-05-03 | Purdue Pharma, L.P. | Opioid dosage forms having dose proportional steady state Cave and AUC and less than dose proportional single dose Cmax |
| US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
| US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
| US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
| EP1830886B1 (en) * | 2004-12-27 | 2016-04-13 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
| US20080268043A1 (en) * | 2005-01-26 | 2008-10-30 | Elan Pharma International Limited | Controlled Release Compositions Comprising an Antipsychotic Agent |
| DE102005019458A1 (en) * | 2005-04-25 | 2006-10-26 | Grünenthal GmbH | Composition, useful in the preparation of pellets and the multi-particular-presentation form, comprises cefuroximaxetil and carrageenan of the group of lambda carrageenan, tau carrageenan and kappa carrageenan |
| US20090023778A1 (en) * | 2005-04-28 | 2009-01-22 | Eisai R&D Management Co., Ltd. | Composition Containing Anti-Dementia Drug |
| CA2609618C (en) * | 2005-05-24 | 2016-01-05 | Flamel Technologies | Novel acetylsalicylic acid formulations |
| US20070020333A1 (en) * | 2005-07-20 | 2007-01-25 | Chin-Chih Chiang | Controlled release of hypnotic agents |
| GB0516604D0 (en) * | 2005-08-12 | 2005-09-21 | Sandoz Ag | Rapidly dispersing/disintegrating compositions |
| CA2616416A1 (en) * | 2005-09-09 | 2007-05-03 | Labopharm, Inc. | Trazodone composition for once a day adminisitiation |
| CA2620018A1 (en) * | 2005-09-28 | 2007-04-12 | Mali Kadosh | Stable combinations of amlodipine besylate and benazepril hydrochloride |
| DE102005048293A1 (en) * | 2005-10-08 | 2007-04-12 | Sanofi-Aventis Deutschland Gmbh | Retard formulation for pralnacasan |
| ATE438381T1 (en) * | 2005-11-18 | 2009-08-15 | Synhton B V | ZOLPIDEME TABLETS |
| ATE489079T1 (en) | 2005-12-29 | 2010-12-15 | Osmotica Kereskedelmi Es Szolgaltata Kft | MULTI-LAYER TABLET WITH TRIPLE RELEASE COMBINATION |
| CZ300698B6 (en) * | 2006-06-16 | 2009-07-22 | Zentiva, A. S. | Metformin-containing tablet |
| FR2906801B1 (en) * | 2006-10-05 | 2008-12-12 | Eurotab Sa | SOLID COMPACT WATER POTABILIZING BILOUD SOLID PRODUCT AND PROCESS FOR PREPARING THE SAME. |
| KR100985254B1 (en) * | 2006-10-30 | 2010-10-04 | 한올바이오파마주식회사 | Controlled release complex composition comprising angiotensin???receptor blockers and HMG-CoA reductase inhibitors |
| US8394845B2 (en) | 2006-10-30 | 2013-03-12 | Hanall Biopharma Co., Ltd. | Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor |
| WO2008105920A1 (en) * | 2007-02-28 | 2008-09-04 | Collegium Pharmaceutical, Inc. | Antihistamine combination |
| EP2123275A1 (en) * | 2007-03-15 | 2009-11-25 | Toyo Boseki Kabushiki Kaisha | Process for production of buprenorphine pharmaceutical preparation to be applied to mouth mucosa |
| US20110020408A1 (en) * | 2007-05-17 | 2011-01-27 | Ranbaxy Laboratories Limited | multilayered modified release formulation comprising amoxicillin and clavulanate |
| US20100172991A1 (en) * | 2007-06-08 | 2010-07-08 | Henry Joseph Horacek | Extended Release Formulation and Methods of Treating Adrenergic Dysregulation |
| MX2009013384A (en) * | 2007-06-08 | 2010-01-25 | Addrenex Pharmaceuticals Inc | Extended release formulation and method of treating adrenergic dysregulation. |
| US8404275B2 (en) | 2007-07-01 | 2013-03-26 | Vitalis Llc | Combination tablet with chewable outer layer |
| WO2009024858A1 (en) * | 2007-08-22 | 2009-02-26 | Aurobindo Pharma Limited | Controlled release dosage form of galantamine |
| RU2469718C2 (en) * | 2007-10-16 | 2012-12-20 | Лабофарм Инк. | Two-layer composition for continuous release of acetaminophen and tramadol |
| JP5651818B2 (en) | 2007-12-17 | 2015-01-14 | パラディン ラブス インコーポレーテッド | Controlled release formulation to prevent misuse |
| FR2927965B1 (en) * | 2008-02-22 | 2010-06-04 | Valeo Materiaux De Friction Sa | METHOD FOR MANUFACTURING FRICTION MATERIAL AND IN PARTICULAR CLUTCH FRICTION CROWN |
| WO2009154810A2 (en) * | 2008-02-25 | 2009-12-23 | Dr. Reddy's Laboratories Ltd. | Delivery systems for multiple active agents |
| WO2009118764A1 (en) * | 2008-03-28 | 2009-10-01 | Panacea Biotec Limited | Pharmaceutical composition comprising diclofenac and paracetamol |
| JP2009256237A (en) * | 2008-04-16 | 2009-11-05 | Daiichi Sankyo Healthcare Co Ltd | Solid preparation |
| WO2010019915A1 (en) * | 2008-08-15 | 2010-02-18 | Depomed Inc. | Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders |
| KR20110079641A (en) | 2008-09-09 | 2011-07-07 | 아스트라제네카 아베 | Method for delivering a pharmaceutical composition to patient in need thereof |
| WO2010045656A2 (en) * | 2008-10-17 | 2010-04-22 | Nectid, Inc. | Novel sglt2 inhibitor dosage forms |
| US20110217371A1 (en) * | 2008-11-10 | 2011-09-08 | Amorepacific Corporation | Controlled-release microparticles and method of preparing same |
| US8486449B2 (en) | 2008-12-16 | 2013-07-16 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
| AU2010206249B2 (en) * | 2009-01-23 | 2015-07-09 | F. Hoffmann-La Roche Ag | Pharmaceutical composition comprising aleglitazar |
| KR101050076B1 (en) * | 2009-02-04 | 2011-07-19 | 한국유나이티드제약 주식회사 | Compositions of Oral Formulations Containing Controlled Release Aceclofenac and Methods for Making the Same |
| WO2010138441A1 (en) * | 2009-05-28 | 2010-12-02 | Aptapharma, Inc. | Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen |
| US20110008432A1 (en) * | 2009-06-25 | 2011-01-13 | Pozen Inc. | Method for Treating a Patient in Need of Aspirin Therapy |
| SG176724A1 (en) | 2009-06-25 | 2012-01-30 | Astrazeneca Ab | Method for treating a patient at risk for developing an nsaid-associated ulcer |
| EP2506709B2 (en) | 2009-12-02 | 2019-10-09 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
| WO2011080716A2 (en) | 2010-01-04 | 2011-07-07 | Wockhardt Limited | Pharmaceutical composition for modified delivery of actives |
| PL2394644T3 (en) * | 2010-05-04 | 2014-11-28 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Trimetazidine Formulation With Different Release Profiles |
| JP2013533241A (en) * | 2010-06-22 | 2013-08-22 | ティダブリューアイ・ファーマシューティカルズ・インコーポレイテッド | Controlled release composition with reduced food effect |
| CN102727496A (en) * | 2011-04-12 | 2012-10-17 | 上海双健现代药物技术咨询有限公司 | Compound antituberculosis drug oral solid preparation and its preparation method |
| CN104105478A (en) | 2011-10-28 | 2014-10-15 | 维塔利斯公司 | Anti-flush compositions |
| CA2860231A1 (en) | 2011-12-28 | 2013-07-04 | Pozen Inc. | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
| ES2558204T3 (en) * | 2012-01-31 | 2016-02-02 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Formulations of flurbiprofen and glucosamine bilayer tablet |
| US20150017242A1 (en) * | 2012-02-20 | 2015-01-15 | Lupin Limited | Bilayer Tablet of Dronedarone |
| WO2013123595A1 (en) | 2012-02-22 | 2013-08-29 | Duchesnay Inc. | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
| US20140072671A1 (en) * | 2012-06-29 | 2014-03-13 | Adam Auerbach | Multi-component oral delivery systems and uses thereof |
| WO2014075155A1 (en) * | 2012-11-14 | 2014-05-22 | Diffucap Chemobras Química E Farmacêutica Ltda | Pharmaceutical combination containing an analgesic agent and an antispasmodic agent |
| PL2919903T3 (en) | 2012-11-14 | 2020-12-14 | W.R. Grace & Co. - Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide |
| RU2521572C1 (en) * | 2012-12-21 | 2014-06-27 | Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской академии наук (ИХР РАН) | Cocrystalline form of fenbufen |
| KR20150126383A (en) * | 2013-03-12 | 2015-11-11 | 바이오히트 오와이제이 | Composition for oral administration for binding aldehydes in the gastrointestinal tract |
| WO2014177900A1 (en) | 2013-04-29 | 2014-11-06 | Clariant Production (France) Sas | Cap for a container |
| WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
| US9452181B2 (en) | 2013-07-22 | 2016-09-27 | Duchesnay Inc. | Composition for the management of nausea and vomiting |
| US10028941B2 (en) | 2013-07-22 | 2018-07-24 | Duchesnay Inc. | Composition for the management of nausea and vomiting |
| WO2015027303A1 (en) * | 2013-08-28 | 2015-03-05 | Diffucap Chemobras Quimica E Farmaceutica Ltda | Method for manufacturing a pharmaceutical combination containing an analgesic agent and an antispasmodic agent and pharmaceutical combination |
| WO2015063669A1 (en) | 2013-10-30 | 2015-05-07 | Wockhardt Limited | Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof |
| TWI595874B (en) | 2014-08-29 | 2017-08-21 | 達契斯奈股份有限公司 | Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
| CN106794148B (en) * | 2014-08-29 | 2018-12-21 | 达切斯内公司 | The multi-mode delivery formulations of doxylamine and pyridoxol and/or its metabolite or salt |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| CA2936740C (en) * | 2014-10-31 | 2017-10-10 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| US10413403B2 (en) * | 2015-07-14 | 2019-09-17 | Boston Scientific Scimed, Inc. | Prosthetic heart valve including self-reinforced composite leaflets |
| MX2018000939A (en) * | 2015-07-23 | 2018-06-07 | Athena Drug Delivery Solutions Pvt Ltd | Zolpidem composition and process for preparing the same. |
| MX2020002078A (en) | 2017-08-24 | 2020-09-21 | Adamas Pharma Llc | Amantadine compositions, preparations thereof, and methods of use. |
| US11819482B2 (en) | 2017-08-29 | 2023-11-21 | Conrig Pharma Aps | Composition comprising suplatast tosilate |
| US20230040902A1 (en) * | 2019-12-19 | 2023-02-09 | Celltrion Inc. | Pharmaceutical Formulation Comprising Cibenzoline or Salt Thereof |
| CN114432300B (en) * | 2022-02-16 | 2023-08-01 | 平顶山市第二人民医院 | Pharmaceutical composition containing bisoprolol and enalapril and process thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5911563B2 (en) * | 1980-02-27 | 1984-03-16 | 日本原子力研究所 | Method for manufacturing multilayer sustained release composites |
| IT1206166B (en) * | 1984-07-26 | 1989-04-14 | Sigma Tau Ind Farmaceuti | DEVICE FOR RELEASING A SUBSTANCE IN A DISSOLUTION FLUID WITH ZERO ORDER KINETICS AND PROCEDURE FOR ITS PREPARATION |
| US4752479A (en) * | 1986-05-27 | 1988-06-21 | Ciba-Geigy Corporaton | Multi vitamin and mineral dietary supplement with controlled release bioavailable iron |
| FR2645152B1 (en) * | 1989-03-30 | 1991-05-31 | Lipha | 3H-PTERIDINONES-4, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM |
| CA2277220A1 (en) * | 1997-01-10 | 1998-07-16 | Abbott Laboratories | Tablet for the controlled release of active agents |
-
1997
- 1997-12-23 FR FR9716402A patent/FR2772615B1/en not_active Expired - Fee Related
-
1998
- 1998-11-12 UA UA2000074216A patent/UA55503C2/en unknown
- 1998-12-11 BR BR9814345-0A patent/BR9814345A/en not_active Application Discontinuation
- 1998-12-11 PT PT98965814T patent/PT1041972E/en unknown
- 1998-12-11 US US09/581,992 patent/US6372255B1/en not_active Expired - Lifetime
- 1998-12-11 HU HU0100406A patent/HU226069B1/en not_active IP Right Cessation
- 1998-12-11 ES ES98965814T patent/ES2182397T3/en not_active Expired - Lifetime
- 1998-12-11 AT AT98965814T patent/ATE223207T1/en active
- 1998-12-11 DK DK98965814T patent/DK1041972T3/en active
- 1998-12-11 RU RU2000120166/14A patent/RU2212885C2/en not_active IP Right Cessation
- 1998-12-11 SK SK932-2000A patent/SK283236B6/en not_active IP Right Cessation
- 1998-12-11 ID IDW20001144A patent/ID26313A/en unknown
- 1998-12-11 CN CNB988124874A patent/CN1163220C/en not_active Expired - Fee Related
- 1998-12-11 WO PCT/EP1998/008100 patent/WO1999033448A1/en active IP Right Grant
- 1998-12-11 EP EP98965814A patent/EP1041972B1/en not_active Expired - Lifetime
- 1998-12-11 JP JP2000526205A patent/JP4451563B2/en not_active Expired - Fee Related
- 1998-12-11 DE DE69807747T patent/DE69807747T2/en not_active Expired - Lifetime
- 1998-12-11 KR KR1020007007039A patent/KR100574207B1/en not_active IP Right Cessation
- 1998-12-11 CA CA002316277A patent/CA2316277C/en not_active Expired - Fee Related
- 1998-12-11 AU AU21606/99A patent/AU743195B2/en not_active Ceased
- 1998-12-11 CZ CZ20002332A patent/CZ291884B6/en not_active IP Right Cessation
- 1998-12-18 AR ARP980106474A patent/AR017897A1/en active IP Right Grant
- 1998-12-22 ZA ZA9811799A patent/ZA9811799B/en unknown
-
2000
- 2000-06-22 NO NO20003289A patent/NO20003289L/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2316277C (en) | Tablet for instant and prolonged release of one or more active substances | |
| EP1469834B1 (en) | Multi-stage oral drug controlled-release system | |
| AU666674B2 (en) | Dosage form for delivering drug in short-time period | |
| JP3718522B2 (en) | Drug delayed delivery dosage form | |
| AP1107A (en) | Tablet with controlled release of alfuzosine chlorydrate. | |
| EP1059917B1 (en) | Pharmaceutical preparation for use in anti-asthma therapy | |
| MX2007001138A (en) | Pharmaceutical multilayer tablet for controlled release of active ingredients with highly ph-dependent solubility. | |
| CA1273876A (en) | Theophylline sustained release tablet | |
| WO2009034541A2 (en) | Controlled release pharmaceutical dosage forms of trimetazidine | |
| JP2004501190A (en) | Rapidly expanding compositions for gastric retention and controlled release of therapeutic agents and dosage forms containing the compositions | |
| AU2003282603A1 (en) | Gastro-retentive levodopa delivery form | |
| EP1755568B1 (en) | Controlled release formulation for oral administration of metformin | |
| EP0235363B1 (en) | Sustained release tablets of theophylline | |
| HRP20010650A2 (en) | Controlled-release compositions of betahistine | |
| CN1486686A (en) | Stomach floating pulsed releasing tablet | |
| MXPA00006213A (en) | Tablet for instant and prolonged release of one or more active substances | |
| CN113456607A (en) | Sacubitril valsartan sodium monolayer osmotic pump controlled release tablet and preparation method thereof | |
| WO2022109962A1 (en) | Zolpidem double-layered osmotic pump controlled release tablet and preparation method therefor | |
| KR100216624B1 (en) | Orally administrable slow-releasing preparations | |
| PL190599B1 (en) | Tablet featured by instantaneous and prolonged release of one or more active substances | |
| WO2005065641A3 (en) | Non-disintegrating oral solid composition of high dose of water soluble drugs | |
| KR100890537B1 (en) | Methods and devices for providing prolonged drug therapy | |
| CN116251069A (en) | Zolpidem tartrate gastric-floating release tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20151211 |